Date: 2013-01-08
Type of information: R&D agreement
Compound: small molecule modulators of protein-protein-interactions
Company: Priaxon (Germany) GSK (UK)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: Priaxon has announced a collaboration with GSK to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modulation of protein-protein interactions (PPIs). This collaboration will work to identify and advance candidates from hits to leads for pre-clinical development, with the long term interest of developing and commercialising drug candidates. The agreement has been signed following a successful pilot project. Financial details as well as therapeutic fields of the collaboration are not disclosed.
Financial terms:
Latest news:
